Autolus Therapeutics plc
Close on Oct 19, 2026
- Market cap
- $423.19M
- P/E (TTM)
- –
- Dividend yield
- –
About Autolus Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
The company is an early commercial-stage biopharmaceutical business that develops, manufactures, and supplies programmed T-cell immunotherapies for patients with cancer and autoimmune conditions. Its lead commercial therapy is AUCATZYL, an autologous CAR T-cell treatment directed against the CD19 antigen for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The firm also advances a pipeline of investigational candidates for additional hematological malignancies, solid tumors, lupus nephritis, and progressive multiple sclerosis. Its recipients and end users are patients treated through authorized specialized hospital treatment centers.
The organization maintains commercial operations in the United States and the United Kingdom, where its product is available through the National Health Service. It operates a dedicated manufacturing facility named the Nucleus in Stevenage, United Kingdom, which provides global product supply, and partners with a third-party distributor in the United States. Its clinical pipeline includes four programs across eight cancer and two autoimmune indications. The provided text does not disclose its corporate headquarters.
Summary of the business section of Autolus Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Autolus Therapeutics plc
- Headquarters
- London, X0
- Address
- The Mediaworks, 191 Wood Lane W12 7FP
- Phone
- 44 20 3829 6230
- Employees
- 754, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- X0
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Reading, United Kingdom
Stock & identifiers
- Ticker
- AUTL
- Exchange
- Nasdaq
- IPO date
- Jun 22, 2018
- Shares outstanding
- 266M, Aug 10, 2026
- Public float
- $548.89M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1730463
- CUSIP
- 05280R100
- ISIN
- US05280R1005
- LEI
- 549300C0KZP8EYROLL02
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christian Itin | Chief Executive Officer, Director | 1,116,009 |
| Cintia Piccina | U.S. CCO & Country Gen Manager | 13,287 |
| Christopher Andrew Vann | Chief Operating Officer | 152,211 |
| Alexander Swan | Chief Human Resources Officer | – |
| Alex Driggs | SVP, Legal Affairs and GC | – |
| Miranda Suzette Neville | Chief Technology Officer | – |
| Robert Dolski | Chief Financial Officer | – |
| Patrick Paul McIlvenny | SVP Finance | – |
| Christopher Michael James Williams | Chief Business Officer | 8,198 |
| Matthias Will | Chief Development Officer | – |
| Linda Bain | Director | – |
| Cynthia M. Butitta | Director | – |
| Ryan Richardson | Director | – |
| Robert Azelby | Director | – |
| Robert Iannone | Director | – |
| Elisabeth Leiderman | Director | – |
| Michael W. Bonney | Director | – |
| Madduri Ravin Rao | Director | – |
| William D. Young | Director | – |
| John E. Berriman | Director | 136,331 |
| Martin Anton Pule | Director | – |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 754 employees, 752 of whom are full-time.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 16, 2026 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 13, 2024 | Late filing | Notification of late filing |
| Jun 22, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 19, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 8, 2018 | Name change | Name changed from Autolus Therapeutics Ltd to Autolus Therapeutics plc |